Phase 1/2 study with our HDAC inhibitor mocetinostat in combination with MedImmune’s PD-L1 inhibitor MEDI4736 in patients with Advanced Solid Tumors and NSCLC

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
Phase 1/2 study with our HDAC inhibitor mocetinostat in combination with MedImmune’s PD-L1 inhibitor MEDI4736 in patients with Advanced Solid Tumors and NSCLC

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.